Oncology

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.

A meta-analysis of 39 studies found similar or slightly better cancer survival for Black veterans compared with White veterans in the VHA.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

The authors used Medicaid claims data to quantify program spending, use of services, and enrollment patterns among Medicaid beneficiaries newly diagnosed with a metastatic vs a nonmetastatic cancer.

The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

Seven oncology leaders reflect on lasting gains in patient care, cost awareness, and collaboration, and what was lost when CMS walked away.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

A population-based study linked male sex, Hispanic ethnicity, and select birth and parental factors to increased EOCRC risk.

The FDA approved sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for metastatic triple-negative breast cancer.

Kerry Rogers, MD, outlines the cardiovascular risks of prolonged BTK inhibitor therapy in CLL and the major sequencing questions that remain unanswered.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and FDA-ready analytics.

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.

Baseline QOL is an independent prognostic factor for survival in AML, with global QOL carrying the largest HR, according to Fabio Efficace, PhD, MSc.

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, as well as early CAR T data in B-cell lymphoma and ITP.

Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.